Collingwood T N, Adams M, Tone Y, Chatterjee V K
Department of Medicine, University of Cambridge, Level 5 Addenbrooke's Hospital, United Kingdom.
Mol Endocrinol. 1994 Sep;8(9):1262-77. doi: 10.1210/mend.8.9.7838159.
Resistance to thyroid hormone (RTH) is usually dominantly inherited and characterized by elevated thyroid hormone levels, impaired feedback inhibition of pituitary TSH production, and variable hormonal responsiveness in peripheral tissues. We have identified 20 different mutations in the thyroid hormone beta-receptor (TR beta) gene in RTH and assayed mutant receptor properties using the TSH alpha subunit gene promoter or promoters containing three different types of positive thyroid response element (TRE). Dominant negative inhibition of wild type TR beta action by mutant receptors was also tested. The mutant receptors exhibited differing transcriptional inhibitory properties and dominant negative potential with the TSH alpha promoter that correlated with their impaired hormone binding, whereas transactivation and dominant negative effects with promoters containing positive TREs varied depending on their configuration. Heterodimeric mutant receptor-retinoid X receptor (RXR) interactions, either in cultured cells or as TRE-bound complexes in gel retardation assays, were uniformly preserved, whereas homodimeric receptor interactions could not be detected in vivo, and in vitro homodimer formation on TREs was variably reduced or absent for some mutant proteins. We correlate these findings with the distribution of receptor mutations that cluster in two areas within the hormone binding domain outside putative dimerization regions and show that artificial mutations that impaired heterodimerization abrogated dominant negative activity. Therefore, we suggest that the dominant negative effect of mutant receptors in the pituitary-thyroid axis generates the characteristic biochemical abnormality of RTH and that variable resistance in other tissues may be due to response element-dependent differences in their dominant negative potential.
甲状腺激素抵抗(RTH)通常为显性遗传,其特征为甲状腺激素水平升高、垂体促甲状腺激素(TSH)分泌的反馈抑制受损以及外周组织中激素反应性各异。我们在RTH患者中鉴定出甲状腺激素β受体(TRβ)基因的20种不同突变,并使用TSHα亚基基因启动子或含有三种不同类型甲状腺激素反应元件(TRE)的启动子来检测突变受体的特性。还测试了突变受体对野生型TRβ作用的显性负性抑制。突变受体在TSHα启动子上表现出不同的转录抑制特性和显性负性潜能,这与其激素结合受损相关,而含有阳性TRE的启动子的反式激活和显性负性效应则因其构型而异。在培养细胞中或凝胶阻滞试验中作为与TRE结合的复合物的异二聚体突变受体-视黄酸X受体(RXR)相互作用均得以保留,而在体内无法检测到同二聚体受体相互作用,并且对于某些突变蛋白,TRE上的体外同二聚体形成可变地减少或缺失。我们将这些发现与聚集在假定二聚化区域之外的激素结合域内两个区域的受体突变分布相关联,并表明损害异二聚化的人工突变消除了显性负性活性。因此,我们认为突变受体在垂体-甲状腺轴中的显性负性效应产生了RTH的特征性生化异常,而其他组织中可变的抵抗可能是由于其显性负性潜能中依赖于反应元件的差异。